fda compounding glp-1 crackdown news today New project announcement: HHS‑OIG is taking a closer look at FDA's oversight of compounded GLP‑1 drugs. Although shortages ended in 2025, some facilities may still be producing these drugs at scale. Our FDA is moving to restrict

June 2026 Update: OROS has begun rolling out USP Residual Solvent Analysis on all newly manufactured batches, screening for trace residual solvents including Acetonitrile, Methanol, DMF, and Dichloromethane as part of our continued commitment to comprehensive batch-level quality control

Histamine Storage and Release

[3] Next-Generation Dual and Multi-Targeted Therapies on the Rise Amycretin: A Promising Dual GLP-1/Amylin Receptor Agonist Also making headlines at ADA 2025 was Amycretin (NNC0487-0111), a novel, unimolecular GLP-1 and amylin receptor agonist under development by Novo Nordisk

Ive learned not to comment on other peoples bodies, which is a shame since Im good at it